Methylone for PTSD. Interview with Transcend Therapeutics CEO Blake Mandell скачать в хорошем качестве

Methylone for PTSD. Interview with Transcend Therapeutics CEO Blake Mandell

My father's PhD advisor at Harvard was Timothy Leary, so I've always had an interest in psychedelics. After decades in the regulatory wilderness, psychedelic products like MDMA are now being developed to treat mental health disorders. But if these drugs are approved there will be a new problem: patient access. The treatments generally require many hours of highly trained mental health provider time per patient. That's not going to scale. Blake Mandell is CEO of Transcend Therapeutics, which seeks to address these challenges with a non-hallucinogenic MDMA analogue called methylone for PTSD. That should mean much less need for clinical supervision of patients and should also take away patient concerns about tripping. Health Business Group https://healthbusinessgroup.com/​​​​​ has two decades of experience in developing robust strategies for companies like Transcend. You can reach us at https://www.healthbusinessgroup.com/c... Subscribe on YouTube or: Spotify https://open.spotify.com/show/2wkphb6... Apple Podcasts https://podcasts.apple.com/us/podcast... Google Podcasts https://podcasts.google.com/feed/aHR0... Many more services https://www.buzzsprout.com/1367974​